Table 1 Common genetic variants from known breast cancer susceptibility loci displaying most significant genome-wide associations with ER-negative breast cancer risk.

From: Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer

Location

Position

Nearest gene

SNP

Alleles

iCOGS/GWAS ER-negative

BRCA1 carriers

Meta-analysis

     

EAF

OR (95% CI)

P

EAF

HR (95% CI)

P

P*

Variants in known loci most significantly associated with overall breast cancer

1p36.2

10563609

PEX14

rs10864459

G/A

0.32

0.90 (0.87–0.93)

2.13 × 10−9

0.31

0.95 (0.91–0.99)

0.01

4.60 × 10−10

1q32.1

202179042

LGR6

rs17489300

A/C

0.4

0.90 (0.87–0.93)

9.37 × 10−10

0.39

0.97 (0.93–1.01)

0.19

1.98 × 10−8

1q32.1

204518842

MDM4

rs4245739

A/C

0.26

1.13 (1.11–1.19)

5.53 × 10−15

0.28

1.09 (1.05–1.14)

6.83 × 10−5

7.71 × 10−18

2p24.1

19184284

2p24.1

rs12710696

C/T

0.36

1.10 (1.06–1.13)

1.70 × 10−8

0.39

1.01 (0.97–1.05)

0.56

1.90 × 10−6

2q14.2

121088182

INHBB

rs11903787

G/A

0.25

0.90 (0.86–0.94)

8.57 × 10−7

0.26

0.91 (0.87–0.96)

2.0 × 10−4

7.24 × 10−10

5p15.3

1280028

TERT

rs2242652

A/G

0.20

1.18 (1.13–1.23)

2.73 × 10−14

0.22

1.22 (1.16–1.28)

2.53 × 10−15

7.58 × 10−28

5p15.3

1282319

TERT

rs7726159

A/C

0.34

1.09 (1.05–1.13)

2.19 × 10−6

0.35

1.07 (1.02–1.11)

1.79 × 10−3

3.31 × 10−8

5p15.3

1297488

TERT

rs2736108

T/C

0.29

0.89 (0.86–0.93)

1.41 × 10−8

0.29

0.89 (0.86–0.93)

4.05 × 10−7

3.05 × 10−14

6q25.1

151918856

ESR1

rs12662670

T/G

0.08

1.20 (1.18–1.32)

8.90 × 10−15

0.09

1.19 (1.11–1.27)

9.67 × 10−7

1.32 × 10−19

6q25.1

151946152

ESR1

rs11155804

A/T

0.34

1.16 (1.12–1.19)

8.18 × 10−18

0.36

1.15 (1.11–1.20)

0.02

3.75 × 10−28

10q21.2

64278682

ZNF365

rs10995190

G/A

0.16

0.89 (0.85–0.93)

3.75 × 10−8

0.16

0.99 (0.94–1.04)

0.66

8.23 × 10−6

10q25.2

114782803

TCF7L2

rs6585202

T/C

0.46

1.06 (1.04–1.10)

3.35 × 10−5

0.47

1.10 (1.05–1.14)

6.08 × 10−6

1.32 × 10−9

11p15.5

1902097

LSP1

rs4980383

C/T

0.44

1.08 (1.05–1.12)

3.02 × 10−6

0.45

1.07 (1.03–1.11)

7.73 × 10−4

9.41 × 10−9

12p11.2

28174817

PTHLH

rs7297051

C/T

0.24

0.86 (0.83–0.89)

1.48 × 10−14

0.23

0.89 (0.85–0.93)

2.89 × 10−7

3.12 × 10−20

12p11.2

28155080

PTHLH

rs10771399

A/G

0.12

0.79 (0.78–0.87)

3.82 × 10−13

0.10

0.86 (0.80–0.91)

2.55 × 10−6

7.18 × 10−18

16q12.1

52599188

TO × 3

rs4784227

C/T

0.24

1.15 (1.11–1.19)

1.11 × 10−14

0.26

1.07 (1.02–1.12)

4.97 × 10−3

6.44 × 10−15

16q12.2

53813367

FTO

rs17817449

T/G

0.41

0.91 (0.89–0.95)

2.83 × 10−7

0.41

0.95 (0.92–0.99)

0.02

5.26 × 10−8

16q12.2

53855291

FTO

rs11075995

T/A

0.24

1.11 (1.07–1.15)

3.30 × 10−8

0.24

1.01 (0.97–1.06)

0.61

1.56 × 10−6

19p13.1

17389704

MERIT40

rs8170

G/A

0.19

1.15 (1.11–1.20)

1.35 × 10−12

0.19

1.17 (1.11–1.23)

7.29 × 10−10

6.64 × 10−21

19p13.1

17393925

ADHB8

rs56069439

C/A

0.30

1.16 (1.13–1.20)

8.25 × 10−19

0.30

1.19 (1.14–1.24)

1.42 × 10−15

1.49 × 10−32

  1. CI, confidence interval; EAF, effect allele frequency; ER, oestrogen receptor; GWAS, genome-wide association studies; HR, hazard ratio; OR, odds ratio; SNP, single-nucleotide polymorphism.
  2. *P values from iCOGS/BCAC and meta-analysis for ER-negative breast cancer were estimated by z-test. P values for BRCA1 carriers were estimated by a kinship-adjusted retrospective likelihood approach.
  3. SNPs with more significant associations with ER-negative disease than known index SNPs from these loci.